Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh
Shafiqul Alam Sarker, Shamima Sultana, Gloria Reuteler, et al.
EBioMedicine (2016) Vol. 4, pp. 124-137
Open Access | Times Cited: 457

Showing 1-25 of 457 citing articles:

Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It
Zeinab Breijyeh, Buthaina Jubeh, Rafik Karaman
Molecules (2020) Vol. 25, Iss. 6, pp. 1340-1340
Open Access | Times Cited: 1124
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection
Robert T. Schooley, Biswajit Biswas, Jason J. Gill, et al.
Antimicrobial Agents and Chemotherapy (2017) Vol. 61, Iss. 10
Open Access | Times Cited: 1041
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kaitlyn E. Kortright, Benjamin K. Chan, Jonathan L. Koff, et al.
Cell Host & Microbe (2019) Vol. 25, Iss. 2, pp. 219-232
Open Access | Times Cited: 921
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Derek Lin, Britt Koskella, Henry C. Lin
World Journal of Gastrointestinal Pharmacology and Therapeutics (2017) Vol. 8, Iss. 3, pp. 162-162
Open Access | Times Cited: 878
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Yi Duan, Cristina Llorente, Sonja Lang, et al.
Nature (2019) Vol. 575, Iss. 7783, pp. 505-511
Open Access | Times Cited: 662
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Danish J. Malik, I. J. Sokolov, Gurinder K. Vinner, et al.
Advances in Colloid and Interface Science (2017) Vol. 249, pp. 100-133
Open Access | Times Cited: 454
Adherent-invasive Escherichia coli in inflammatory bowel disease
Carolina Palmela, Caroline Chevarin, Zhilu Xu, et al.
Gut (2017) Vol. 67, Iss. 3, pp. 574-587
Closed Access | Times Cited: 421
Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen
Dwayne R. Roach, Chung Yin Leung, Marine Henry, et al.
Cell Host & Microbe (2017) Vol. 22, Iss. 1, pp. 38-47.e4
Open Access | Times Cited: 402
Phage therapy: From biological mechanisms to future directions
Steffanie A. Strathdee, Graham F. Hatfull, Vivek K. Mutalik, et al.
Cell (2023) Vol. 186, Iss. 1, pp. 17-31
Open Access | Times Cited: 395
Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections
Nicola Principi, Ettore Silvestri, Susanna Esposito
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 381
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Graham F. Hatfull, Rebekah M. Dedrick, Robert T. Schooley
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 197-211
Open Access | Times Cited: 368
Ménage à trois in the human gut: interactions between host, bacteria and phages
Mohammadali Khan Mirzaei, Corinne F. Maurice
Nature Reviews Microbiology (2017) Vol. 15, Iss. 7, pp. 397-408
Closed Access | Times Cited: 329
Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles
Lucy L. Furfaro, Matthew S. Payne, Barbara J. Chang
Frontiers in Cellular and Infection Microbiology (2018) Vol. 8
Open Access | Times Cited: 302
Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review
Krystyna Dąbrowska
Medicinal Research Reviews (2019) Vol. 39, Iss. 5, pp. 2000-2025
Open Access | Times Cited: 281
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review
Saartje Uyttebroek, Baixing Chen, Jolien Onsea, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 8, pp. e208-e220
Closed Access | Times Cited: 258
A Review of Phage Therapy against Bacterial Pathogens of Aquatic and Terrestrial Organisms
Janis H. Doss, Kayla J Culbertson, Delilah Hahn, et al.
Viruses (2017) Vol. 9, Iss. 3, pp. 50-50
Open Access | Times Cited: 255
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial
Lorenz Leitner, Aleksandre Ujmajuridze, Ніна Чанішвілі, et al.
The Lancet Infectious Diseases (2020) Vol. 21, Iss. 3, pp. 427-436
Closed Access | Times Cited: 253
Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
Matteo Bassetti, Garyphallia Poulakou, Étienne Ruppé, et al.
Intensive Care Medicine (2017) Vol. 43, Iss. 10, pp. 1464-1475
Closed Access | Times Cited: 249
Current challenges and future opportunities of phage therapy
Diana P. Pires, Ana Rita Costa, Graça Pinto, et al.
FEMS Microbiology Reviews (2020) Vol. 44, Iss. 6, pp. 684-700
Open Access | Times Cited: 231
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Athanasios Kakasis, Gerasimia Panitsa
International Journal of Antimicrobial Agents (2018) Vol. 53, Iss. 1, pp. 16-21
Closed Access | Times Cited: 219
Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
Rebekah M. Dedrick, Bailey E. Smith, Madison Cristinziano, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 1, pp. 103-112
Open Access | Times Cited: 218
Problems with the concept of gut microbiota dysbiosis
Harald Brüssow
Microbial Biotechnology (2019) Vol. 13, Iss. 2, pp. 423-434
Open Access | Times Cited: 203
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Tiffany Luong, Ann-Charlott Salabarria, Dwayne R. Roach
Clinical Therapeutics (2020) Vol. 42, Iss. 9, pp. 1659-1680
Open Access | Times Cited: 200
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Sheng Liu, Wenjing Zhao, Ping Lan, et al.
Protein & Cell (2020) Vol. 12, Iss. 5, pp. 331-345
Open Access | Times Cited: 199
Current State of Compassionate Phage Therapy
Shawna McCallin, Jessica C. Sacher, Jan Zheng, et al.
Viruses (2019) Vol. 11, Iss. 4, pp. 343-343
Open Access | Times Cited: 192
Page 1 - Next Page

Scroll to top